The Open Targets Blog
JUNE 18, 2025
integrated their GWAS findings with functional genomics data from relevant tissues, identifying 700 genes with high confidence of being involved in osteoarthritis, and eight biological processes key to the disease development, including circadian clock and glial cell functions. GWAS credible sets from Hatzikotoulas et al. GCST90566795 ).
The Open Targets Blog
MAY 9, 2024
In December 2023, we introduced the pharmacogenetics widget in the Open Targets Platform, which brings in data from PharmGKB on the influence of genetic variation on drug responses. Pharmacogenetics examines the link between genetics and drug response, helping in the prioritisation of drug targets that minimise the risk of adverse effects.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Broad Institute
MAY 30, 2024
Introduction to Pharmacogenetics By Rose Circeo May 30, 2024 Breadcrumb Home Introduction to Pharmacogenetics The Primer on Medical and Population Genetics is a series of weekly lectures on genetics topics related to human populations and disease.
The Open Targets Blog
MARCH 20, 2024
We have implemented this analysis for eight sources of target-disease association evidence where there is enough information available to make an assessment. The assessment is tailored to each dataset; this is detailed in our target-disease evidence documentation. million evidence. is included as independent evidence.
ASPET
SEPTEMBER 16, 2024
Glioblastoma (GBM) is a disease of the whole brain, with infiltrative tumor cells protected by an intact BBB. GBM has a poor prognosis despite aggressive treatment, in part due to lack of adequate drug permeability at the BBB. Standard of care GBM therapies include radiation and cytotoxic chemotherapy that lead to DNA damage.
ASPET
AUGUST 4, 2023
These findings have important clinical implications as PMAT could represent a novel molecular marker to help inform disease prognosis and predict response to 131 I-mIBG therapy. PMAT is expressed intracellularly in neuroblastoma cells, transports mIBG and thus could impact tumor retention and response to 131 I-mIBG therapy.
The Open Targets Blog
NOVEMBER 30, 2023
The new page can be accessed from the target-disease associations page when searching for targets associated with a disease, and clicking on the target prioritisation factors tab. Target prioritisation view for Crohn's Disease. Clicking on one of the cells will bring up the data informing the assessment.
Expert insights. Personalized for you.
77 
Let's personalize your content